Publication | Open Access

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaHigh-risk Myelodysplastic SyndromeHematologyPharmacologyAcute Myeloid LeukaemiaPharmacotherapyPhase 2OncologyAplastic AnemiaMyeloid Neoplasia